ID   MELK_HUMAN              Reviewed;         651 AA.
AC   Q14680; A6P3A7; A6P3A8; B1AMQ6; B7Z1E6; B7Z5M5; B7Z6Q7; B7Z6R8;
AC   B7Z6Y0; B7Z7Q1; D3DRP8; F5H0Y0; F5H2R4; F5H689; Q7L3C3;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 3.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Maternal embryonic leucine zipper kinase;
DE            Short=hMELK;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Eg3;
DE            Short=pEg3 kinase;
DE   AltName: Full=Protein kinase PK38;
DE            Short=hPK38;
DE   AltName: Full=Tyrosine-protein kinase MELK;
DE            EC=2.7.10.2;
GN   Name=MELK; Synonyms=KIAA0175;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).
RA   Katagiri T., Lin M.;
RT   "Identification of MELK whose expression was highly up-regulated in
RT   breast cancers.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=8724849; DOI=10.1093/dnares/3.1.17;
RA   Nagase T., Seki N., Ishikawa K., Tanaka A., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. V.
RT   The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 3:17-24(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3; 4; 5; 7 AND 8).
RC   TISSUE=Spleen, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH ZNF622, AND FUNCTION IN PHOSPHORYLATION OF ZNF622.
RC   TISSUE=Keratinocyte;
RX   PubMed=11802789; DOI=10.1042/0264-6021:3610597;
RA   Seong H.-A., Gil M., Kim K.-T., Kim S.-J., Ha H.;
RT   "Phosphorylation of a novel zinc-finger-like protein, ZPR9, by murine
RT   protein serine/threonine kinase 38 (MPK38).";
RL   Biochem. J. 361:597-604(2002).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25B.
RX   PubMed=12400006; DOI=10.1038/sj.onc.1205870;
RA   Davezac N., Baldin V., Blot J., Ducommun B., Tassan J.P.;
RT   "Human pEg3 kinase associates with and phosphorylates CDC25B
RT   phosphatase: a potential role for pEg3 in cell cycle regulation.";
RL   Oncogene 21:7630-7641(2002).
RN   [9]
RP   INTERACTION WITH PPP1R8, AUTOPHOSPHORYLATION, MUTAGENESIS OF ASP-150;
RP   THR-345; THR-387; THR-409; THR-415; THR-428; THR-446; THR-460;
RP   THR-466; THR-478 AND THR-518, PHOSPHORYLATION AT THR-478, AND
RP   FUNCTION.
RX   PubMed=14699119; DOI=10.1074/jbc.M311466200;
RA   Vulsteke V., Beullens M., Boudrez A., Keppens S., Van Eynde A.,
RA   Rider M.H., Stalmans W., Bollen M.;
RT   "Inhibition of spliceosome assembly by the cell cycle-regulated
RT   protein kinase MELK and involvement of splicing factor NIPP1.";
RL   J. Biol. Chem. 279:8642-8647(2004).
RN   [10]
RP   PHOSPHORYLATION AT THR-167, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   THR-167.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A.,
RA   Boudeau J., Hawley S.A., Udd L., Maekelae T.P., Hardie D.G.,
RA   Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK
RT   subfamily, including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [11]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=16266996; DOI=10.1158/0008-5472.CAN-04-4531;
RA   Gray D., Jubb A.M., Hogue D., Dowd P., Kljavin N., Yi S., Bai W.,
RA   Frantz G., Zhang Z., Koeppen H., de Sauvage F.J., Davis D.P.;
RT   "Maternal embryonic leucine zipper kinase/murine protein serine-
RT   threonine kinase 38 is a promising therapeutic target for multiple
RT   cancers.";
RL   Cancer Res. 65:9751-9761(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25B.
RX   PubMed=15908796; DOI=10.4161/cc.4.6.1716;
RA   Mirey G., Chartrain I., Froment C., Quaranta M., Bouche J.P.,
RA   Monsarrat B., Tassan J.P., Ducommun B.;
RT   "CDC25B phosphorylated by pEg3 localizes to the centrosome and the
RT   spindle poles at mitosis.";
RL   Cell Cycle 4:806-811(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-505, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   PHOSPHORYLATION AT THR-167; SER-343; SER-356; TYR-367; THR-398;
RP   THR-409; SER-431; THR-494; SER-505 AND SER-529.
RX   PubMed=16628004; DOI=10.4161/cc.5.8.2683;
RA   Badouel C., Korner R., Frank-Vaillant M., Couturier A., Nigg E.A.,
RA   Tassan J.P.;
RT   "M-phase MELK activity is regulated by MPF and MAPK.";
RL   Cell Cycle 5:883-889(2006).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   CALCIUM-BINDING, PHOSPHORYLATION AT THR-56; TYR-163; THR-167; SER-171;
RP   SER-253; SER-336; SER-343; SER-356; SER-391; THR-398; SER-407;
RP   SER-431; THR-494; SER-505; SER-529 AND THR-539, AND MUTAGENESIS OF
RP   CYS-29; CYS-70; CYS-89; ASP-150; CYS-154; TYR-163; CYS-168; CYS-169;
RP   SER-171; CYS-204; 283-ASP--ASP-285; CYS-286 AND CYS-339.
RX   PubMed=16216881; DOI=10.1074/jbc.M507274200;
RA   Beullens M., Vancauwenbergh S., Morrice N., Derua R., Ceulemans H.,
RA   Waelkens E., Bollen M.;
RT   "Substrate specificity and activity regulation of protein kinase
RT   MELK.";
RL   J. Biol. Chem. 280:40003-40011(2005).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16159311; DOI=10.1042/BC20050041;
RA   Chartrain I., Couturier A., Tassan J.P.;
RT   "Cell-cycle-dependent cortical localization of pEg3 protein kinase in
RT   Xenopus and human cells.";
RL   Biol. Cell 98:253-263(2006).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF BCL2L14, AND MUTAGENESIS OF ASP-150.
RX   PubMed=17280616; DOI=10.1186/bcr1650;
RA   Lin M.L., Park J.H., Nishidate T., Nakamura Y., Katagiri T.;
RT   "Involvement of maternal embryonic leucine zipper kinase (MELK) in
RT   mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic
RT   member of the Bcl-2 family.";
RL   Breast Cancer Res. 9:R17-R17(2007).
RN   [18]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17960622; DOI=10.1002/ijc.23189;
RA   Marie S.K., Okamoto O.K., Uno M., Hasegawa A.P., Oba-Shinjo S.M.,
RA   Cohen T., Camargo A.A., Kosoy A., Carlotti C.G. Jr., Toledo S.,
RA   Moreira-Filho C.A., Zago M.A., Simpson A.J., Caballero O.L.;
RT   "Maternal embryonic leucine zipper kinase transcript abundance
RT   correlates with malignancy grade in human astrocytomas.";
RL   Int. J. Cancer 122:807-815(2008).
RN   [19]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17722061; DOI=10.1002/jnr.21471;
RA   Nakano I., Masterman-Smith M., Saigusa K., Paucar A.A., Horvath S.,
RA   Shoemaker L., Watanabe M., Negro A., Bajpai R., Howes A., Lelievre V.,
RA   Waschek J.A., Lazareff J.A., Freije W.A., Liau L.M., Gilbertson R.J.,
RA   Cloughesy T.F., Geschwind D.H., Nelson S.F., Mischel P.S.,
RA   Terskikh A.V., Kornblum H.I.;
RT   "Maternal embryonic leucine zipper kinase is a key regulator of the
RT   proliferation of malignant brain tumors, including brain tumor stem
RT   cells.";
RL   J. Neurosci. Res. 86:48-60(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-498; SER-505;
RP   THR-518 AND SER-529, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-431 AND SER-505, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=19671159; DOI=10.1186/bcr2350;
RA   Pickard M.R., Green A.R., Ellis I.O., Caldas C., Hedge V.L.,
RA   Mourtada-Maarabouni M., Williams G.T.;
RT   "Dysregulated expression of Fau and MELK is associated with poor
RT   prognosis in breast cancer.";
RL   Breast Cancer Res. 11:R60-R60(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-498; SER-505
RP   AND SER-529, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [25]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=20861186; DOI=10.1158/0008-5472.CAN-10-1295;
RA   Hebbard L.W., Maurer J., Miller A., Lesperance J., Hassell J.,
RA   Oshima R.G., Terskikh A.V.;
RT   "Maternal embryonic leucine zipper kinase is upregulated and required
RT   in mammary tumor-initiating cells in vivo.";
RL   Cancer Res. 70:8863-8873(2010).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21145462; DOI=10.1016/j.cell.2010.11.028;
RA   Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D.,
RA   Janmey P.A., Lemmon M.A.;
RT   "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane
RT   targets by binding acidic phospholipids.";
RL   Cell 143:966-977(2010).
RN   [27]
RP   DEVELOPMENTAL STAGE, AND PHOSPHORYLATION.
RX   PubMed=20420823; DOI=10.1016/j.yexcr.2010.04.019;
RA   Badouel C., Chartrain I., Blot J., Tassan J.P.;
RT   "Maternal embryonic leucine zipper kinase is stabilized in mitosis by
RT   phosphorylation and is partially degraded upon mitotic exit.";
RL   Exp. Cell Res. 316:2166-2173(2010).
RN   [28]
RP   INDUCTION.
RX   PubMed=21806965; DOI=10.1016/j.bbrc.2011.07.060;
RA   Choi S., Ku J.L.;
RT   "Resistance of colorectal cancer cells to radiation and 5-FU is
RT   associated with MELK expression.";
RL   Biochem. Biophys. Res. Commun. 412:207-213(2011).
RN   [29]
RP   INDUCTION.
RX   PubMed=21558073; DOI=10.1093/neuonc/nor023;
RA   Nakano I., Joshi K., Visnyei K., Hu B., Watanabe M., Lam D.,
RA   Wexler E., Saigusa K., Nakamura Y., Laks D.R., Mischel P.S.,
RA   Viapiano M., Kornblum H.I.;
RT   "Siomycin A targets brain tumor stem cells partially through a MELK-
RT   mediated pathway.";
RL   Neuro-oncol. 13:622-634(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-498; SER-505
RP   AND SER-529, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-56; ARG-219; LYS-333; ILE-348 AND
RP   MET-460.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various
CC       processes such as cell cycle regulation, self-renewal of stem
CC       cells, apoptosis and splicing regulation. Has a broad substrate
CC       specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and
CC       ZNF622. Acts as an activator of apoptosis by phosphorylating and
CC       activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably
CC       by mediating phosphorylation of CDC25B, promoting localization of
CC       CDC25B to the centrosome and the spindle poles during mitosis.
CC       Plays a key role in cell proliferation and carcinogenesis.
CC       Required for proliferation of embryonic and postnatal multipotent
CC       neural progenitors. Phosphorylates and inhibits BCL2L14, possibly
CC       leading to affect mammary carcinogenesis by mediating inhibition
CC       of the pro-apoptotic function of BCL2L14. Also involved in the
CC       inhibition of spliceosome assembly during mitosis by
CC       phosphorylating ZNF622, thereby contributing to its redirection to
CC       the nucleus. May also play a role in primitive hematopoiesis.
CC       {ECO:0000269|PubMed:11802789, ECO:0000269|PubMed:12400006,
CC       ECO:0000269|PubMed:14699119, ECO:0000269|PubMed:15908796,
CC       ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027, ECO:0000269|PubMed:16216881}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:16216881}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation of the T-loop
CC       at Thr-167 and Ser-171: in contrast to other members of the SNF1
CC       subfamily, phosphorylation at Thr-167 is not mediated by
CC       STK11/LKB1 but via autophosphorylation instead. Inhibited by
CC       calcium-binding. Kinase activity is also regulated by reducing
CC       agents: dithiothreitol (DTT) or reduced glutathione are required
CC       for kinase activity in vitro; such dependence is however not due
CC       to the presence of disulfide bonds. {ECO:0000269|PubMed:16216881}.
CC   -!- SUBUNIT: Monomer. Interacts with ZNF622 and PPP1R8.
CC       {ECO:0000269|PubMed:11802789, ECO:0000269|PubMed:14699119}.
CC   -!- INTERACTION:
CC       Q9BZR8:BCL2L14; NbExp=4; IntAct=EBI-1046702, EBI-1385773;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16159311,
CC       ECO:0000269|PubMed:21145462}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:16159311, ECO:0000269|PubMed:21145462}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1;
CC         IsoId=Q14680-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14680-2; Sequence=VSP_044715;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q14680-3; Sequence=VSP_045208;
CC       Name=4;
CC         IsoId=Q14680-4; Sequence=VSP_045209;
CC       Name=5;
CC         IsoId=Q14680-5; Sequence=VSP_045430;
CC       Name=6;
CC         IsoId=Q14680-6; Sequence=VSP_045431;
CC       Name=7;
CC         IsoId=Q14680-7; Sequence=VSP_046760;
CC         Note=No experimental confirmation available.;
CC       Name=8;
CC         IsoId=Q14680-8; Sequence=VSP_046759;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in placenta, kidney, thymus, testis,
CC       ovary and intestine. {ECO:0000269|PubMed:8724849}.
CC   -!- DEVELOPMENTAL STAGE: Increases during G2/M phase compared to
CC       interphase. Protein level decreases when cells exit mitosis,
CC       probably due to degradation. {ECO:0000269|PubMed:20420823}.
CC   -!- INDUCTION: Up-regulated in many cancers cells. Up-regulated upon
CC       treatment with radiation or 5-fluorouracil (5-FU) in colorectal
CC       cancer cells, suggesting that it might be associated with
CC       increased resistance of colorectal cells against radiation and 5-
CC       FU. Down-regulated upon siomycin A, a thiazole antibiotic,
CC       treatment, leading to inhibit tumor growth in vivo.
CC       {ECO:0000269|PubMed:21558073, ECO:0000269|PubMed:21806965}.
CC   -!- DOMAIN: The KA1 domain mediates binding to phospholipids and
CC       targeting to membranes. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated: autophosphorylation of the T-loop at Thr-
CC       167 and Ser-171 is required for activation. Thr-478
CC       phosphorylation during mitosis promotes interaction with PPP1R8
CC       (Probable). {ECO:0000305|PubMed:14699119,
CC       ECO:0000305|PubMed:14976552, ECO:0000305|PubMed:16216881,
CC       ECO:0000305|PubMed:16628004, ECO:0000305|PubMed:20420823}.
CC   -!- DISEASE: Note=Defects in MELK are associated with some cancers,
CC       such as brain or breast cancers. Expression is dramatically
CC       increased in aggressive undifferentiated tumors, correlating with
CC       poor patient outcome in breast and brain cancers, suggesting a
CC       role in tumor-initiating cells and proliferation via its function
CC       in cell proliferation regulation.
CC   -!- MISCELLANEOUS: Potential therapeutic target for treatment of
CC       somatic tumors, such as brain and breast cancers, down-regulation
CC       of MELK inhibiting tumorigenesis (PubMed:17960622,
CC       PubMed:20861186). {ECO:0000305|PubMed:17960622,
CC       ECO:0000305|PubMed:20861186}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA11492.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MELKID43360ch9p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB183427; BAF73615.1; -; mRNA.
DR   EMBL; AB183428; BAF73616.1; -; mRNA.
DR   EMBL; D79997; BAA11492.2; ALT_INIT; mRNA.
DR   EMBL; AK293284; BAH11482.1; -; mRNA.
DR   EMBL; AK293447; BAH11508.1; -; mRNA.
DR   EMBL; AK299164; BAH12961.1; -; mRNA.
DR   EMBL; AK300761; BAH13343.1; -; mRNA.
DR   EMBL; AK300821; BAH13354.1; -; mRNA.
DR   EMBL; AK301131; BAH13416.1; -; mRNA.
DR   EMBL; AK302374; BAH13687.1; -; mRNA.
DR   EMBL; AL354932; CAI11034.2; -; Genomic_DNA.
DR   EMBL; AL442063; CAI11034.2; JOINED; Genomic_DNA.
DR   EMBL; AL442063; CAI16995.2; -; Genomic_DNA.
DR   EMBL; AL354932; CAI16995.2; JOINED; Genomic_DNA.
DR   EMBL; CH471071; EAW58303.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58304.1; -; Genomic_DNA.
DR   EMBL; BC014039; AAH14039.1; -; mRNA.
DR   CCDS; CCDS59123.1; -. [Q14680-7]
DR   CCDS; CCDS59124.1; -. [Q14680-8]
DR   CCDS; CCDS59125.1; -. [Q14680-2]
DR   CCDS; CCDS59126.1; -. [Q14680-6]
DR   CCDS; CCDS59127.1; -. [Q14680-5]
DR   CCDS; CCDS59128.1; -. [Q14680-4]
DR   CCDS; CCDS6606.1; -. [Q14680-1]
DR   RefSeq; NP_001243614.1; NM_001256685.1. [Q14680-7]
DR   RefSeq; NP_001243616.1; NM_001256687.1. [Q14680-8]
DR   RefSeq; NP_001243617.1; NM_001256688.1. [Q14680-2]
DR   RefSeq; NP_001243618.1; NM_001256689.1. [Q14680-6]
DR   RefSeq; NP_001243619.1; NM_001256690.1. [Q14680-5]
DR   RefSeq; NP_001243621.1; NM_001256692.1. [Q14680-4]
DR   RefSeq; NP_001243622.1; NM_001256693.1. [Q14680-3]
DR   RefSeq; NP_055606.1; NM_014791.3. [Q14680-1]
DR   RefSeq; XP_011516378.1; XM_011518076.2. [Q14680-1]
DR   RefSeq; XP_011516379.1; XM_011518077.1. [Q14680-1]
DR   RefSeq; XP_011516380.1; XM_011518078.2. [Q14680-1]
DR   RefSeq; XP_011516381.1; XM_011518079.1. [Q14680-1]
DR   RefSeq; XP_011516383.1; XM_011518081.2. [Q14680-6]
DR   RefSeq; XP_011516384.1; XM_011518082.2. [Q14680-6]
DR   RefSeq; XP_011516385.1; XM_011518083.2. [Q14680-6]
DR   RefSeq; XP_011516386.1; XM_011518084.2. [Q14680-6]
DR   UniGene; Hs.184339; -.
DR   PDB; 4BKY; X-ray; 1.83 A; A=2-340.
DR   PDB; 4BKZ; X-ray; 2.20 A; A=2-340.
DR   PDB; 4BL1; X-ray; 2.60 A; A=2-340.
DR   PDB; 4D2P; X-ray; 2.55 A; A/B/C/D=1-336.
DR   PDB; 4D2T; X-ray; 2.70 A; A/B/C/D=1-336.
DR   PDB; 4D2V; X-ray; 2.45 A; A/B/C/D=1-336.
DR   PDB; 4D2W; X-ray; 1.92 A; A/B/C/D=1-336.
DR   PDB; 4IXP; X-ray; 2.75 A; A=1-340.
DR   PDB; 4UMP; X-ray; 2.30 A; A/B/C/D=1-336.
DR   PDB; 4UMQ; X-ray; 2.60 A; A=1-336.
DR   PDB; 4UMR; X-ray; 3.00 A; A=1-336.
DR   PDB; 4UMT; X-ray; 1.98 A; A=1-336.
DR   PDB; 4UMU; X-ray; 2.02 A; A=1-336.
DR   PDB; 5IH8; X-ray; 1.85 A; A=3-330.
DR   PDB; 5IH9; X-ray; 1.79 A; A=3-330.
DR   PDB; 5IHA; X-ray; 1.96 A; A=3-330.
DR   PDB; 5IHC; X-ray; 2.14 A; A=3-330.
DR   PDB; 5K00; X-ray; 1.77 A; A=3-330.
DR   PDBsum; 4BKY; -.
DR   PDBsum; 4BKZ; -.
DR   PDBsum; 4BL1; -.
DR   PDBsum; 4D2P; -.
DR   PDBsum; 4D2T; -.
DR   PDBsum; 4D2V; -.
DR   PDBsum; 4D2W; -.
DR   PDBsum; 4IXP; -.
DR   PDBsum; 4UMP; -.
DR   PDBsum; 4UMQ; -.
DR   PDBsum; 4UMR; -.
DR   PDBsum; 4UMT; -.
DR   PDBsum; 4UMU; -.
DR   PDBsum; 5IH8; -.
DR   PDBsum; 5IH9; -.
DR   PDBsum; 5IHA; -.
DR   PDBsum; 5IHC; -.
DR   PDBsum; 5K00; -.
DR   ProteinModelPortal; Q14680; -.
DR   SMR; Q14680; -.
DR   BioGrid; 115171; 23.
DR   IntAct; Q14680; 3.
DR   MINT; MINT-7944803; -.
DR   STRING; 9606.ENSP00000298048; -.
DR   BindingDB; Q14680; -.
DR   ChEMBL; CHEMBL4578; -.
DR   GuidetoPHARMACOLOGY; 2102; -.
DR   iPTMnet; Q14680; -.
DR   PhosphoSitePlus; Q14680; -.
DR   BioMuta; MELK; -.
DR   DMDM; 50400857; -.
DR   EPD; Q14680; -.
DR   MaxQB; Q14680; -.
DR   PaxDb; Q14680; -.
DR   PeptideAtlas; Q14680; -.
DR   PRIDE; Q14680; -.
DR   DNASU; 9833; -.
DR   Ensembl; ENST00000298048; ENSP00000298048; ENSG00000165304. [Q14680-1]
DR   Ensembl; ENST00000536329; ENSP00000443550; ENSG00000165304. [Q14680-5]
DR   Ensembl; ENST00000536860; ENSP00000439792; ENSG00000165304. [Q14680-8]
DR   Ensembl; ENST00000536987; ENSP00000439184; ENSG00000165304. [Q14680-4]
DR   Ensembl; ENST00000541717; ENSP00000437804; ENSG00000165304. [Q14680-7]
DR   Ensembl; ENST00000543751; ENSP00000441596; ENSG00000165304. [Q14680-6]
DR   Ensembl; ENST00000545008; ENSP00000445452; ENSG00000165304. [Q14680-2]
DR   GeneID; 9833; -.
DR   KEGG; hsa:9833; -.
DR   UCSC; uc003zzn.5; human. [Q14680-1]
DR   CTD; 9833; -.
DR   DisGeNET; 9833; -.
DR   GeneCards; MELK; -.
DR   HGNC; HGNC:16870; MELK.
DR   HPA; HPA017214; -.
DR   MIM; 607025; gene.
DR   neXtProt; NX_Q14680; -.
DR   OpenTargets; ENSG00000165304; -.
DR   PharmGKB; PA134902874; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00870000136390; -.
DR   HOGENOM; HOG000233023; -.
DR   HOVERGEN; HBG106273; -.
DR   InParanoid; Q14680; -.
DR   KO; K08799; -.
DR   OMA; YELHETI; -.
DR   OrthoDB; EOG091G05V9; -.
DR   PhylomeDB; Q14680; -.
DR   TreeFam; TF314032; -.
DR   SignaLink; Q14680; -.
DR   SIGNOR; Q14680; -.
DR   ChiTaRS; MELK; human.
DR   GeneWiki; MELK; -.
DR   GenomeRNAi; 9833; -.
DR   PRO; PR:Q14680; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000165304; -.
DR   CleanEx; HS_MELK; -.
DR   ExpressionAtlas; Q14680; baseline and differential.
DR   Genevisible; Q14680; HS.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; IDA:UniProtKB.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:InterPro.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:InterPro.
DR   GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   CDD; cd14078; STKc_MELK; 1.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033624; MARK/par1.
DR   InterPro; IPR034673; MELK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24346; PTHR24346; 1.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Calcium;
KW   Cell cycle; Cell membrane; Complete proteome; Kinase; Lipid-binding;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    651       Maternal embryonic leucine zipper kinase.
FT                                /FTId=PRO_0000086323.
FT   DOMAIN       11    263       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      602    651       KA1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00565}.
FT   NP_BIND      17     25       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      282    321       UBA-like.
FT   REGION      326    651       Autoinhibitory region.
FT   ACT_SITE    132    132       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      40     40       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      56     56       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     163    163       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     167    167       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14976552,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     171    171       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     253    253       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     336    336       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     343    343       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     356    356       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     367    367       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16628004}.
FT   MOD_RES     391    391       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     398    398       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     407    407       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MOD_RES     409    409       Phosphothreonine.
FT                                {ECO:0000269|PubMed:16628004}.
FT   MOD_RES     431    431       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     478    478       Phosphothreonine.
FT                                {ECO:0000269|PubMed:14699119}.
FT   MOD_RES     494    494       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     498    498       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     505    505       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     518    518       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     529    529       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     529    529       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:16628004}.
FT   MOD_RES     539    539       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16216881}.
FT   VAR_SEQ       1    194       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045208.
FT   VAR_SEQ       1    135       MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKI
FT                                MDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKI
FT                                FMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYV
FT                                HSQGYAHRDLKP -> MVLE (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045209.
FT   VAR_SEQ       1     87       MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKI
FT                                MDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKI
FT                                FMVLE -> MMNFSNIMNYMKLLGQ (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_045430.
FT   VAR_SEQ       1     48       MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKI
FT                                MDKNTLG -> MMNFSNIMNYMKLLGQ (in isoform
FT                                6). {ECO:0000303|Ref.1}.
FT                                /FTId=VSP_045431.
FT   VAR_SEQ      88    158       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044715.
FT   VAR_SEQ      88    135       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046759.
FT   VAR_SEQ     352    392       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046760.
FT   VARIANT      56     56       T -> M (in dbSNP:rs35233455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040794.
FT   VARIANT     219    219       K -> R (in dbSNP:rs35142210).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040795.
FT   VARIANT     333    333       R -> K (in dbSNP:rs34655121).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040796.
FT   VARIANT     348    348       T -> I (in dbSNP:rs55845414).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040797.
FT   VARIANT     460    460       T -> M (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs144052967).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040798.
FT   MUTAGEN      29     29       C->V: Abolishes dependence to reducing
FT                                agents; when associated with V-70; A-89;
FT                                A-154; A-168; A-169; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN      70     70       C->V: Abolishes dependence to reducing
FT                                agents; when associated with V-29; A-89;
FT                                A-154; A-168; A-169; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN      89     89       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-154; A-168; A-169; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     150    150       D->A: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:14699119,
FT                                ECO:0000269|PubMed:16216881,
FT                                ECO:0000269|PubMed:17280616}.
FT   MUTAGEN     154    154       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-168; A-169; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     163    163       Y->F: Abolishes autophosphorylation on
FT                                tyrosine but still active on exogenous
FT                                substrates.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     167    167       T->A: Abolishes activation of
FT                                serine/threonine-protein kinase activity
FT                                and has only weak activity.
FT                                {ECO:0000269|PubMed:14976552}.
FT   MUTAGEN     167    167       T->D,E: Phosphomimetic mutant that has
FT                                similar kinase activity as wild-type.
FT                                {ECO:0000269|PubMed:14976552}.
FT   MUTAGEN     168    168       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-154; A-169; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     169    169       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-154; A-168; A-204; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     171    171       S->A: Abolishes activation of
FT                                serine/threonine-protein kinase activity
FT                                and has only weak activity.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     171    171       S->D: Inactive.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     204    204       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-154; A-168; A-169; A-286 and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     283    285       DDD->KKK: Inactive.
FT                                {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     286    286       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-154; A-168; A-169; A-204; and A-
FT                                339. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     339    339       C->A: Abolishes dependence to reducing
FT                                agents; when associated with V-29; V-70;
FT                                A-89; A-154; A-168; A-169; A-204 and A-
FT                                286. {ECO:0000269|PubMed:16216881}.
FT   MUTAGEN     345    345       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     387    387       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     409    409       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     415    415       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     428    428       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     446    446       T->A: Inhibits interaction with PPP1R8.
FT                                {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     460    460       T->A: Inhibits interaction with PPP1R8.
FT                                {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     466    466       T->A: Inhibits interaction with PPP1R8.
FT                                {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     478    478       T->A: Strongly inhibits interaction with
FT                                PPP1R8. Enhances enzymatic activity.
FT                                {ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     518    518       T->A: No effect on interaction with
FT                                PPP1R8. {ECO:0000269|PubMed:14699119}.
FT   CONFLICT     69     69       I -> M (in Ref. 3; BAH12961).
FT                                {ECO:0000305}.
FT   CONFLICT    398    398       T -> A (in Ref. 3; BAH12961).
FT                                {ECO:0000305}.
FT   CONFLICT    428    428       T -> A (in Ref. 3; BAH11482).
FT                                {ECO:0000305}.
FT   CONFLICT    474    474       C -> R (in Ref. 3; BAH13343).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       P -> L (in Ref. 3; BAH13354).
FT                                {ECO:0000305}.
FT   TURN          4      6       {ECO:0000244|PDB:4BKY}.
FT   HELIX         7      9       {ECO:0000244|PDB:5K00}.
FT   STRAND       11     19       {ECO:0000244|PDB:5K00}.
FT   STRAND       20     22       {ECO:0000244|PDB:4D2T}.
FT   STRAND       24     30       {ECO:0000244|PDB:5K00}.
FT   TURN         31     33       {ECO:0000244|PDB:5K00}.
FT   STRAND       36     43       {ECO:0000244|PDB:5K00}.
FT   HELIX        44     47       {ECO:0000244|PDB:5K00}.
FT   HELIX        48     50       {ECO:0000244|PDB:5K00}.
FT   HELIX        51     62       {ECO:0000244|PDB:5K00}.
FT   STRAND       72     77       {ECO:0000244|PDB:5K00}.
FT   STRAND       79     87       {ECO:0000244|PDB:5K00}.
FT   HELIX        94    101       {ECO:0000244|PDB:5K00}.
FT   HELIX       106    125       {ECO:0000244|PDB:5K00}.
FT   HELIX       135    137       {ECO:0000244|PDB:5K00}.
FT   STRAND      138    140       {ECO:0000244|PDB:5K00}.
FT   STRAND      146    148       {ECO:0000244|PDB:5K00}.
FT   STRAND      157    159       {ECO:0000244|PDB:4UMP}.
FT   STRAND      163    166       {ECO:0000244|PDB:4IXP}.
FT   HELIX       172    174       {ECO:0000244|PDB:5K00}.
FT   HELIX       177    181       {ECO:0000244|PDB:5K00}.
FT   HELIX       187    204       {ECO:0000244|PDB:5K00}.
FT   HELIX       214    223       {ECO:0000244|PDB:5K00}.
FT   HELIX       234    243       {ECO:0000244|PDB:5K00}.
FT   HELIX       248    250       {ECO:0000244|PDB:5K00}.
FT   HELIX       254    258       {ECO:0000244|PDB:5K00}.
FT   HELIX       261    264       {ECO:0000244|PDB:5K00}.
FT   TURN        265    267       {ECO:0000244|PDB:5K00}.
FT   STRAND      279    281       {ECO:0000244|PDB:4BKZ}.
FT   HELIX       284    291       {ECO:0000244|PDB:5K00}.
FT   STRAND      294    296       {ECO:0000244|PDB:5K00}.
FT   HELIX       298    306       {ECO:0000244|PDB:5K00}.
FT   HELIX       312    326       {ECO:0000244|PDB:5K00}.
SQ   SEQUENCE   651 AA;  74642 MW;  57F05CDC6122E570 CRC64;
     MKDYDELLKY YELHETIGTG GFAKVKLACH ILTGEMVAIK IMDKNTLGSD LPRIKTEIEA
     LKNLRHQHIC QLYHVLETAN KIFMVLEYCP GGELFDYIIS QDRLSEEETR VVFRQIVSAV
     AYVHSQGYAH RDLKPENLLF DEYHKLKLID FGLCAKPKGN KDYHLQTCCG SLAYAAPELI
     QGKSYLGSEA DVWSMGILLY VLMCGFLPFD DDNVMALYKK IMRGKYDVPK WLSPSSILLL
     QQMLQVDPKK RISMKNLLNH PWIMQDYNYP VEWQSKNPFI HLDDDCVTEL SVHHRNNRQT
     MEDLISLWQY DHLTATYLLL LAKKARGKPV RLRLSSFSCG QASATPFTDI KSNNWSLEDV
     TASDKNYVAG LIDYDWCEDD LSTGAATPRT SQFTKYWTES NGVESKSLTP ALCRTPANKL
     KNKENVYTPK SAVKNEEYFM FPEPKTPVNK NQHKREILTT PNRYTTPSKA RNQCLKETPI
     KIPVNSTGTD KLMTGVISPE RRCRSVELDL NQAHMEETPK RKGAKVFGSL ERGLDKVITV
     LTRSKRKGSA RDGPRRLKLH YNVTTTRLVN PDQLLNEIMS ILPKKHVDFV QKGYTLKCQT
     QSDFGKVTMQ FELEVCQLQK PDVVGIRRQR LKGDAWVYKR LVEDILSSCK V
//
